- Home
- MESO vs QDEL Comparison
MESO vs QDEL Comparison
Compare MESO & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- QDEL
- Stock Information
- Founded
- MESO 2004
- QDEL 1979
- Country
- MESO Australia
- QDEL United States
- Employees
- MESO N/A
- QDEL N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- QDEL Medical Specialities
- Sector
- MESO Health Care
- QDEL Health Care
- Exchange
- MESO Nasdaq
- QDEL Nasdaq
- Market Cap
- MESO 1.8B
- QDEL 1.7B
- IPO Year
- MESO N/A
- QDEL N/A
- Fundamental
- Price
- MESO $16.02
- QDEL $28.21
- Analyst Decision
- MESO Strong Buy
- QDEL Hold
- Analyst Count
- MESO 2
- QDEL 6
- Target Price
- MESO $24.00
- QDEL $39.33
- AVG Volume (30 Days)
- MESO 159.9K
- QDEL 1.8M
- Earning Date
- MESO 08-28-2025
- QDEL 11-05-2025
- Dividend Yield
- MESO N/A
- QDEL N/A
- EPS Growth
- MESO N/A
- QDEL N/A
- EPS
- MESO N/A
- QDEL N/A
- Revenue
- MESO $17,198,000.00
- QDEL $2,714,400,000.00
- Revenue This Year
- MESO $440.77
- QDEL N/A
- Revenue Next Year
- MESO $110.74
- QDEL $2.65
- P/E Ratio
- MESO N/A
- QDEL N/A
- Revenue Growth
- MESO 191.39
- QDEL N/A
- 52 Week Low
- MESO $9.61
- QDEL $19.50
- 52 Week High
- MESO $22.00
- QDEL $49.45
- Technical
- Relative Strength Index (RSI)
- MESO 52.88
- QDEL 62.10
- Support Level
- MESO $14.32
- QDEL $20.31
- Resistance Level
- MESO $15.61
- QDEL $23.25
- Average True Range (ATR)
- MESO 0.57
- QDEL 1.84
- MACD
- MESO 0.11
- QDEL 0.70
- Stochastic Oscillator
- MESO 87.78
- QDEL 99.77
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.